Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

ARIAD Pharmaceuticals, Inc. announced preliminary findings from two ongoing clinical trials evaluating oral ridaforolimus in combination with trastuzumab in patients with resistant, metastatic breast cancer and with bevacizumab in heavily pretreated patients with refractory, metastatic solid tumors. Abstracts describing these data have been submitted for presentation at major medical meetings to be held later this year. ARIAD is developing ridaforolimus, an investigational mTOR inhibitor, in collaboration with its partner, Merck and Co, Inc.

Today in Drug Interactions...keeping you current

Probable Drug Interaction Between Warfarin and Hormonal Contraceptives
Annals of Pharmacotherapy, 12/03/09

Does Simvastatin Cause More Myotoxicity Compared with Other Statins
Annals of Pharmacotherapy, 12/03/09

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
BMC Infectious Diseases, 12/03/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address